Table of Content

30 March 2020, Volume 7 Issue 1

Previous Issue    Next Issue

Guidelines and consensus

Consensus for clinical application of molecular diagnosis on hepatobiliary carcinoma

Society for hepatobiliary, Medical society of western retuned scholars association; Society for molecular diagnosis, Chinese research hospital Association, SMD/CRHA; Expert committee for liver cancer, Chinese society of clinical oncology; Professional committee for the prevention, control of hepatobiliary, pancreatic diseases, Chinese preventive medicine association; Expert committee for liver cancer, Asia pacific alliance of liver diseases

2020, 7(1):  24-31. 

Asbtract ( 155 )   PDF (1640KB) ( 211 )  

References | Related Articles | Metrics

Original article

Comparison of gene mutational status between primary colorectal carcinoma and paired synchronous/metachronous liver metastasis by next-generation

Li Weihua, Li Yan, Guo Lei, Ying Jianming

2020, 7(1):  39-44. 

Asbtract ( 130 )   PDF (1792KB) ( 49 )  

References | Related Articles | Metrics

Purpose: To compare the gene mutational status between primary colorectal carcinoma (CRC) and paired synchronous/metachronous liver metastasis. Methods: KRAS, NRAS, BRAF and PIK3CA mutations were analyzed in 29 patients with primary and paired synchronous liver metastatic CRC, and in 26 patients with primary and paired metachronous liver metastatic CRC using next-generation sequencing (NGS). Results: Same mutation profiles of KRAS, NRAS, BRAF or PIK3CA between primary and paired synchronous liver metastatic CRCs were observed in 27 of 29 patients (93.1%). Of 2 patients with discordant mutational status, a KRAS mutation was detected in the primary tumor and one of liver metastatic tumors in a patient, but no mutation was observed in the other liver metastatic lesion. A PIK3CA mutation was observed in primary tumor but not the metastatic tumor in the other patient. Moreover, same mutation profiles between primary and paired metachronous liver metastatic CRCs were observed in 21 of 26 patients (80.8%), which was significantly lower than those in paired primary and synchronous liver metastatic CRCs (P =0.010). Of 5 patients with discordant mutational status, KRAS, NRAS, or PIK3CA mutations were observed in the metastatic tumors but not the primary tumors in 4 patients, whereas a KRAS mutation was detected in the primary tumor but not the metastatic tumor in 1 patient. Conclusions: The gene mutational discrepancies are more frequently observed in paired primary/metachronous liver metastatic CRCs than paired primary/synchronous liver metastatic CRCs.